Dx Assays

Dx Assays is a specialized contract research organization (CRO) that provides end-to-end molecular diagnostic (MDx) assay development services. Founded in 2008 as a joint venture between QIAGEN and BioMérieux, the company was fully acquired by QIAGEN in 2012 and operates as a key center for diagnostic innovation in Singapore. Dx Assays focuses on the design, development, and clinical validation of assays for various platforms, including PCR and Next-Generation Sequencing (NGS). The company is a critical partner for pharmaceutical firms seeking to develop companion diagnostics to support personalized medicine. Its expertise spans from early-stage assay design to regulatory submission and commercial manufacturing support. By leveraging its deep technical knowledge, Dx Assays helps partners accelerate the path from biomarker discovery to a market-ready diagnostic test.